-
D. Boral Capital Downgrades Collplant Holdings Inc. (CLGN) to Hold
-
CollPlant (CLGN) Misses Q3 EPS by 41c, Misses on Revenue
-
CollPlant establishes US logistics center for distribution expansion
-
CollPlant bioink outperforms Matrigel in Technion study
-
CollPlant completes non-clinical studies for photocurable dermal filler
-
CollPlant (CLGN) Tops Q2 EPS by 37c
-
CollPlant hires Bowman Bagley as VP of North America commercial operations
-
CollPlant (CLGN) Files for 1.27M Share Offering by Selling Stockholders
-
CollPlant (CLGN) Receives New EU Patent
-
CollPlant (CLGN) Announces 1.2M Share Offering at $3/sh
-
CollPlant (CLGN) Tops Q1 EPS by 47c
-
CollPlant (CLGN) Expands Distribution for its VergenixSTR Product in Europe and Asia
-
CollPlant (CLGN) Provides a Corporate Update
-
H.C. Wainwright Reiterates Buy Rating on Collplant Holdings Inc. (CLGN)
-
CollPlant (CLGN) Misses Q3 EPS by 9c
-
CollPlant (CLGN) Misses Q2 EPS by 2c
-
CollPlant and Stratasys (SSYS) Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
-
EF Hutton Starts Collplant Holdings Inc. (CLGN) at Buy

